IGF-1 LR3 at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic 83-amino acid analog of endogenous IGF-1. Two structural modifications distinguish it from native IGF-1: a 13-amino acid N-terminal extension (MFPAMPLLSLFVNGSR) and substitution of glutamic acid at position 3 with arginine. These changes dramatically reduce its affinity for insulin-like growth factor binding proteins (IGFBPs), which normally sequester circulating IGF-1 and limit its activity.
The result is a half-life of approximately 20 - 30 hours compared to ~20 minutes for native IGF-1, with substantially greater bioavailability at target tissues. IGF-1 LR3 binds and activates the IGF-1 receptor (IGF-1R) with potency similar to native IGF-1, triggering downstream PI3K/Akt and MAPK/ERK signaling cascades that promote cellular proliferation, differentiation, protein synthesis, and satellite cell activation in skeletal muscle.
In research settings, IGF-1 LR3 has demonstrated significant anabolic effects in animal models: increased muscle mass, accelerated recovery from muscle damage, enhanced nitrogen retention, and promotion of hyperplasia (new muscle fiber formation) in addition to hypertrophy. It also exhibits systemic effects including enhanced lipolysis, nitrogen retention, and potentially anti-catabolic activity.
Human safety and efficacy data are largely absent - no clinical trials have assessed IGF-1 LR3 in healthy adults. Use in the performance community is extrapolated from preclinical models and the pharmacological profile of native IGF-1. The risk of promoting pre-malignant cell proliferation is a significant theoretical concern given IGF-1R's role in cancer biology.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.